U.S., Jan. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07314320) titled 'A Study to Detect Radioactivity of [14C]-OPC-167832 in Urine and Feces in Healthy Men' on Dec. 18, 2025.
Brief Summary: The purpose of this study is to determine the relative amounts of radioactivity excreted in urine and feces following a single oral dose of [14C]-OPC-167832 in healthy male participants.
Study Start Date: Nov. 20, 2023
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers
Intervention:
DRUG: [14C]-OPC-167832
Oral suspension
Recruitment Status: COMPLETED
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....